FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...